LCN2 and familial dilated cardiomyopathy: Evaluating serum NGAL as a standalone biomarker appears to be effective for dogs with DCM, offering promising insights, particularly in light of the lack of veterinary literature on NGAL’s relationship with early-stage DCM in dogs.